SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy-Reference-Cited by-同舟云学术

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy

Published:2017-05-18 Issue:5 Volume:18 Page:1083
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Kawanami Daiji,Matoba Keiichiro,Takeda Yusuke,Nagai Yosuke,Akamine Tomoyo,Yokota Tamotsu,Sango Kazunori^ORCID,Utsunomiya Kazunori

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/18/5/1083/pdf

Reference76 articles.

1. Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes

2. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

3. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON

4. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

5. Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions;Biomedicines;2024-05-15

2. Quercetin prevented diabetic nephropathy by inhibiting renal tubular epithelial cell apoptosis via the PI3K/AKT pathway;Phytotherapy Research;2024-05-09

3. Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3);BMJ Open Diabetes Research & Care;2024-05

4. Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohort;Immunobiology;2024-05

5. Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis;Frontiers in Pharmacology;2024-04-17